Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

MacroGenics signs on Gilead as newest DART partner

Executive Summary

Antibody therapeutics developer MacroGenics Inc. has granted Gilead Sciences Inc. rights to four preclinical programs based on its Dual-Affinity Re-Targeting (DART) bi-specific antibody-generating platform. The specific targets for the collaboration were not disclosed.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register